PTC Therapeutics (PTCT) Stock Looks Expensive As Its 175% Run Draws Focus

PTC Therapeutics has delivered a powerful multi year share price run, yet the recent pullback and fresh gene therapy deal leave a clear question for you as an investor: Is the current valuation still grounded in what the business is generating in sales, or has the stock moved ahead of its commercial footprint?

• Over the past 3 years the stock has climbed about 175%, which puts a lot of weight on whether the revenue base can support that kind of re rating.
• The acquisition of the ST-920 Fabry disease gene therapy program, now headed toward a planned FDA filing by late 2026, can reshape expectations for future sales mix and the timing of potential cash inflows from a one time treatment model.
• There is a second opinion on PTC Therapeutics worth weighing. See what analysts think PTC Therapeutics's shares could be worth.

The issue now is whether the current share price is justified by PTC Therapeutics' sales when you stack it up against Fair Ratio.

If you want to test this same question on other gene therapy and biotech stocks, run the numbers across our 30 high quality undervalued stocks to see how their sales compare with current prices.

Is PTC Therapeutics Getting Expensive on Sales?

P/S is usually the cleanest way to frame a research stage biotech like PTC Therapeutics, because sales arrive well before consistent profits. Despite the fresh interest around the ST-920 Fabry gene therapy deal, the stock currently trades on a P/S of 5.2x, compared with about 12.5x for the broader Biotechs industry and a peer average near 12.5x. That headline discount on revenue looks wide at first glance.

The Fair Ratio model, which folds in PTC Therapeutics' growth profile, margins, size and risk, points to a lower P/S than where the shares trade today. That leaves the current 5.2x above the level implied by those fundamentals, so on this yardstick the stock screens as overvalued even though it is priced below typical biotech peers. For you as a shareholder, the key question is whether future commercial delivery on programs like ST-920 can justify paying a richer multiple than the tailored benchmark suggests. Explore the numbers behind PTC Therapeutics's P/S valuation.

The PTC Therapeutics Narrative: What Would Justify Today's Price?

Narratives pick up where the valuation puzzle for PTC Therapeutics leaves off by spelling out which paths for growth, margins and earnings would need to play out for the shares to be worth materially more or materially less than they are today, and sit on Simply Wall St's Community page so you can see them in context. Each scenario ties a fair value estimate to a specific mix of potential catalysts and setbacks, which helps you track over time which version of events is actually unfolding.

One of the top community narratives on PTC Therapeutics: 39% undervalued

"Advancing pipeline and capital moves enhance revenue stability and earnings visibility, and highlight potential undervaluation versus long-term growth prospects..."

Discover why this Narrative puts PTC Therapeutics at 39% undervalued.

One more PTC Therapeutics signal investors should not ignore

Valuation only tells part of the story for PTC Therapeutics. Recent insider share sales flagged by our checks raise a separate question about internal conviction that is worth inspecting in detail. See the recent insider selling flagged for PTC Therapeutics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com